Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women

Overview of attention for article published in New England Journal of Medicine, July 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

So far, Altmetric has seen 1035 X posts from 988 X users, with an upper bound of 4,872,943 followers.

RT @NEJM: In the PURPOSE 1 trial, researchers evaluated the efficacy and safety of twice-yearly subcutaneous lenacapavir or daily F/TAF for…

The paper on lencapavir in "NEJM" “Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women” 2/3 https://t.co/T9NbmGneYI

RT @NEJM: Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) https://t.co/MMqEYZps…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1031 additional X posts.